Altre lingue TG Therapeutics, Inc.

Azioni

TGTX

US88322Q1085

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 24/04/2024			Variaz. 5gg	Var. 1 gen.
13,98 ^USD	-1,96%		+1,16%	-18,15%

18/04	TG Therapeutics si aggiudica il contratto con i Veterans Affairs per il farmaco Briumvi contro la sclerosi multipla	MT
18/04	Tg Therapeutics, Inc. si aggiudica un contratto nazionale con il Dipartimento degli Affari dei Veterani per Briumvi come anti-Cd20 preferito per le forme recidivanti di sclerosi multipla	CI

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

TG Therapeutics Announces Additional Data Presentations for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	19/04
Sector Update: Health Care Stocks Mixed in Late Afternoon Trading	18/04
Sector Update: Health Care	18/04
TG Therapeutics Wins Veterans Affairs Contract for Multiple Sclerosis Drug Briumvi	18/04
TG Therapeutics Announces Additional Data Presentations for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	18/04
TG Therapeutics Awarded National Contract by the Department of Veterans Affairs for BRIUMVI as the Preferred Anti-CD20 for Relapsing Forms of Multiple Sclerosis	18/04
Tg Therapeutics, Inc. Awards National Contract by the Department of Veterans Affairs for Briumvi as the Preferred Anti-Cd20 for Relapsing Forms of Multiple Sclerosis	18/04
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	16/04
TG Therapeutics Announces Presentation of Data for BRIUMVI® (ublituximab-xiiy) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	15/04
Tg Therapeutics Insider Sold Shares Worth $351,340, According to a Recent SEC Filing	13/03
TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® (ublituximab) in Multiple Sclerosis at the American Academy of Neurology 2024 Annual Meeting	08/03
TG Therapeutics Announces Presentation of Data for BRIUMVI in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	04/03
TG Therapeutics Says Updated Data in Briumvi Study Shows Manageable Safety, Tolerability Profile	01/03
TG Therapeutics Announces Presentation of Data for BRIUMVI® in Multiple Sclerosis at the Americas Committee for Treatment and Research in Multiple Sclerosis Annual Forum	01/03
Sector Update: Health Care Stocks Softer Wednesday Afternoon	28/02
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surge	28/02
TG Therapeutics Narrows Q4 Net Loss, Revenue Jumps; Shares Surging in Pre-Trade	28/02
TG Therapeutics: Q4 Earnings Snapshot	28/02
Earnings Flash (TGTX) TG THERAPEUTICS Posts Q4 Revenue $44M, vs. Street Est of $40.1M	28/02
TG Therapeutics Provides Business Update and Reports Fourth Quarter and Year-End 2023 Financial Results	28/02

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue TG Therapeutics, Inc.

Azioni

TGTX

US88322Q1085

Altre lingue

Filtri